Method for predicting and evaluating responsiveness to cancer treatment with DNA-damaging chemotherapeutic agents
View Patent ↗Provided herein are methods directed to the prediction and early assessment of the efficacy of cancer treatment regimens, in particular in patients undergoing therapy with a DNA-damaging chemotherapeutic agent, by determining expression levels of certain proteins found to be useful as biomarkers in circulating tumor cells obtained from the patient both prior to and post-treatment.
1. A method for predicting the efficacy of treatment with a DNA-damaging chemotherapeutic agent in a patient diagnosed with breast cancer and treating breast cancer, the method comprising:
isolating circulating breast tumor cells by dielectrophoresis field-flow fractionation from a blood sample obtained from the patient,
determining a baseline expression level of one or more proteins selected from the group consisting of topoisomerase I, RAD51, Ki-67, and ABCG2 in the isolated circulating breast tumor cells prior to treatment of the patient with a chemotherapeutic agent to thereby predict the responsiveness of the tumor cells to treatment with the DNA-damaging chemotherapeutic agent,
wherein
for topoisomerase I, elevated baseline expression levels indicate a predisposition to responsiveness to treatment with the DNA-damaging therapeutic agent and suppressed baseline expression levels indicate a predisposition for unresponsiveness to treatment with the DNA-damaging therapeutic agent;
for RAD51, elevated baseline expression levels indicate a predisposition for unresponsiveness to treatment with the DNA-damaging agent and suppressed baseline expression levels indicate a predisposition to responsiveness to treatment;
for Ki-67, elevated baseline expression levels indicate a predisposition to responsiveness to treatment with the DNA-damaging therapeutic agent and suppressed baseline expression levels indicate a predisposition for unresponsiveness to treatment,
for ABCG2, elevated baseline expression levels indicate a predisposition for unresponsiveness to treatment with the DNA-damaging agent and suppressed baseline expression levels indicate a predisposition to responsiveness to treatment,
wherein determining whether a baseline expression level of the protein is elevated or suppressed is based upon a comparison to the mean and/or median baseline expression level of the protein in circulating tumor cells of the overall study population, and
administering a therapeutically effective amount of the DNA-damaging therapeutic agent to the patient, wherein the DNA-damaging therapeutic agent comprises irinotecan modified by releasable covalent attachment to one or more poly(ethylene glycol) polymers.
2. The method of claim 1 , wherein the DNA-damaging therapeutic agent is etirinotecan pegol.
3. The method of claim 1 , wherein the cancer is metastatic breast cancer.
4. The method of claim 1 , wherein the baseline expression levels of the one or more proteins and the expression levels of the one or more proteins following treatment are determined based upon the percentage of positive cells and/or mean fluorescent intensity of the circulating tumor cells stained for detection of the one or more proteins.